View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
March 20, 2020updated 12 Jul 2022 11:57am

NantKwest doses first patient in Merkel cell carcinoma therapy trial

NantKwest has dosed the first patient in a Phase II trial of natural killer cells for second and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors.

NantKwest has dosed the first patient in a Phase II trial of natural killer cells for second and third-line Merkel cell carcinoma (MCC) in patients who are refractory to immune checkpoint inhibitors.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial will evaluate the company’s off-the-shelf CD16-targeted natural killer (haNK) cells and ImmunityBio ’s IL-15 superagonist N-803 and Avelumab.

The single-arm study will enrol 43 patients who failed all standard of care treatments for MCC, including checkpoint therapy.

NantKwest and ImmunityBio chairman and CEO Patrick Soon-Shiong said: “With over 70% of patients failing checkpoint inhibitors in solid tumours, it is vital to develop novel and effective therapeutic options.

“Checkpoint and CAR-T therapies only target the T-cell, which is a small portion of effector killer cells, and often result in substantial side effects. These side effects make those therapies unusable for many patients.”

The combination therapy by NantKwest has been designed to activate the innate immune system to generate immunological memory against tumours, resulting in immunogenic cell death.

Previous study on non-targeted aNK cells has reported clinical responses either alone or in combination with N-803.

NantKwest adult medical affairs senior vice-president John Lee said: “The current study builds on this approach using a PD-L1 antibody that will bind to the high affinity CD16 receptor on haNK cells to potentially help target PD-L1 tumour cells.

“The N-803 superagonist has been shown to enhance the body’s NK and T cells to also help attack the tumour cells. The goal of this work is to provide real hope for these patients using the power of our combination therapies.”

MCC is a type of skin cancer. Patients with metastatic or locally advanced MCC have an extremely poor prognosis.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena